12 January 2017

Big Data Will Influence Service Delivery in Clinical Trials: Interview with KCR’s CEO

KCR’s CEO Mike Jagielski talks on key issues and challenges in clinical study design at PCT 2016

Berlin – 12 January 2017 – Benefits from shared responsibilities between sponsor and contract research organization (CRO), patient-centric approach and the potential impact of big data on clinical trial services – these are the main themes discussed by Mike Jagielski, CEO of KCR, who took part in the “Ask the Expert” program held during the recent Partnership in Clinical Trials (PCT) 2016. The program was a stream of interviews with those industry thought leaders present at the event.

The interview with Mr. Jagielski was opened with a question about partnerships between  Sponsor and CRO. According to the CEO this relation is not about empowerment but rather about mutual understanding of responsibilities and decision making processes. “In my opinion a CRO takes part in the drug development process only for a period of time. The project is the Sponsor’s ‘baby’ and we have to respect that. Therefore, we cannot take away the empowerment from the pharma company. Clarity on shared responsibilities is key to an effective cooperation.”

Watch the 1st Part on “The Benefits of Empowering a CRO”

In the second part of the interview Mr. Jagielski talked about recent and upcoming trends in the CRO industry. One of the main topics nowadays is a “patient-centric approach” in clinical trials. Mr. Jagielski commented: “This theme is not new, however it will shape the studies’ conduct for the next few years. We should be careful though not to narrow the patient-centric approach down to developing new tech tools for patients, as not everybody is able to use them for different reasons. We should be broader when discussing innovative ways of engaging patients.”

Mr. Jagielski also highlighted big data and its influence on clinical trials design as one of the biggest challenges clinical trials are currently facing. The recent merger between IMS and Quintiles is an important step to creating a new service category by employing big data.  “What it will mean for the CRO sector in general, what the influence will be, I am very excited to see,” Mr. Jagielski summarized.

Watch the 2nd Part on Patient Centric Approach and the Biggest Challenges in Clinical Trials

If you would like to see the whole interview, click here.

If you would like to learn more about KCR services please contact Joanna Lewandowska, PR & Marketing, at joanna.lewandowska@kcrcro.com. Please include your full contact details in the query.

About KCR
KCR is a Contract Research Organization (CRO) providing strategic clinical development solutions for the pharmaceutical, biotechnology and medical device industries in Europe, Israel and the U.S. More than 300 professionals support clients with full-service capabilities across our three main service areas: Trial Execution (TE), Functional Service Provision (FS) and Late Phase (LP). Focusing on knowledge, quality and innovation, KCR delivers high value solutions customized to clients' needs. Headquartered in Berlin, Germany, KCR operates across 19 countries in Europe as well as the U.S. For more information, visit www.kcrcro.com.

KCR: We see human behind every number.

Joanna Lewandowska
Associate Director, PR & Marketing
mobile: (+48) 605 053 164
pr@kcrcro.com